Brisbane patients seeking affordable access to one of the most prescribed HIV regimens can access generic Bictegravir+Emtricitabine+TAF at significantly reduced cost, maintaining the same high resistance barrier and single-tablet simplicity as the brand.
|
FAQ: How does Biktarvy's resistance barrier compare to older HIV medications? Bictegravir, the integrase inhibitor in Biktarvy, has demonstrated a notably high barrier to resistance in clinical studies — meaning the virus needs to develop multiple specific mutations simultaneously before treatment failure occurs, which is significantly harder for HIV to achieve compared to some older drug classes. This is one of the key reasons it's recommended as a preferred first-line regimen in most current international HIV treatment guidelines. |